Cell therapy strategies for COVID-19: Current approaches and potential applications.
Mark M ZakiEmal LeshaKhaled SaidKiavash KiaeeLindsey R Robinson-McCarthyHaydy GeorgeAngy HannaEvan AppletonSonglei LiuAlex H M NgParastoo KhoshakhlaghGeorge M ChurchPublished in: Science advances (2021)
Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating severe COVID-19 presentations due to their customizability and regenerative function. This review summarizes COVID-19 pathogenesis, respective areas where cell therapies have potential, and the ongoing 89 cell therapy trials in COVID-19 as of 1 January 2021.
Keyphrases
- coronavirus disease
- cell therapy
- sars cov
- stem cells
- mesenchymal stem cells
- respiratory syndrome coronavirus
- end stage renal disease
- oxidative stress
- newly diagnosed
- ejection fraction
- chronic kidney disease
- human health
- risk assessment
- early onset
- brain injury
- peritoneal dialysis
- risk factors
- prognostic factors
- subarachnoid hemorrhage